News
This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation
Few industries in the U.S. are growing at a quicker pace than legal marijuana. According to a fairly recent report from Marijuana Business Daily, entitled "Marijuana Business Factbook 2017," legal pot
Why Sarepta Therapeutics Stock Gained 10.7% in July
Sarepta Therapeutics (NASDAQ: SRPT), a biotech developing novel treatments for rare disorders, saw its shares rise by a healthy 10.7% last month, according to S&P Global Market Intelligence. The
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
It's been a pretty good year for Juno Therapeutics (NASDAQ: JUNO) so far. The clinical-stage biotech's share price is up more than 50% year-to-date. Its financial position in the first quarter looked
Here's Why Pacific Biosciences of California Is Surging Today
Shares of Pacific Biosciences of California (NASDAQ: PACB), a purveyor of high-accuracy genomic sequencing kits, is marching higher after reporting second-quarter earnings and a big order from a
BASTIDE : Nombre d'actions et de droits de vote au 31 juillet 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street
Why OraSure Technologies, Inc. Jumped Higher Today
OraSure Technologies (NASDAQ: OSUR) is up 16.5% at 12:08 p.m. EDT after reporting stellar second-quarter earnings Wednesday afternoon.Revenue was up 28% year over year. More impressively, there was a
Why Wright Medical Group Shares Are Spiking Higher Today
Shares of Wright Medical Group (NASDAQ: WMGI) were trading 10% higher earlier today after management reported second-quarter financial results that outpaced industry watchers' forecasts.Wright Medical
Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
Shares of clinical-stage biopharma Curis, Inc. (NASDAQ: CRIS) dropped over 14% this morning after the company released second-quarter 2017 financial results and provided an update on a phase 2 trial
Here's Why Dynavax Technologies Corporation Stock Shot Up 64.2% in July
In July, a 12-to-1 Food and Drug Administration advisory committee vote in favor of Dynavax Technologies Corporation's (NASDAQ: DVAX) experimental hepatitis B vaccine allayed previous concerns that
Genomic Health, Inc.: Still Waiting for Reimbursement
Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
ResMed Tops Expectations but Falls Anyway
Medical-device maker ResMed (NYSE: RMD) reported its fiscal fourth-quarter results after the market closed on Tuesday, Aug. 1. The continuous positive airway pressure (CPAP) pioneer reported modest
3 Reasons the Best Is Yet to Come for Celgene
Celgene Corp.'s (NASDAQ: CELG) second-quarter revenue and sales came in nearly 50% higher than they were two short years ago, yet the company doesn't appear to be anywhere near peaking. A flurry of